TY - JOUR A1 - Rimola, Vittoria A1 - Osthues, Tabea A1 - Königs, Vanessa A1 - Geisslinger, Gerd A1 - Sisignano, Marco T1 - Oxaliplatin causes transient changes in TRPM8 channel activity T2 - International journal of molecular sciences N2 - Oxaliplatin is a third-generation platinum-based anticancer drug that is widely used as first-line treatment for colorectal carcinoma. Patients treated with oxaliplatin develop an acute peripheral pain several hours after treatment, mostly characterized by cold allodynia as well as a long-term chronic neuropathy. These two phenomena seem to be causally connected. However, the underlying mechanisms that trigger the acute peripheral pain are still poorly understood. Here we show that the activity of the transient receptor potential melastatin 8 (TRPM8) channel but not the activity of any other member of the TRP channel family is transiently increased 1 h after oxaliplatin treatment and decreased 24 h after oxaliplatin treatment. Mechanistically, this is connected with activation of the phospholipase C (PLC) pathway and depletion of phosphatidylinositol 4,5-bisphosphate (PIP2) after oxaliplatin treatment. Inhibition of the PLC pathway can reverse the decreased TRPM8 activity as well as the decreased PIP2-concentrations after oxaliplatin treatment. In summary, these results point out transient changes in TRPM8 activity early after oxaliplatin treatment and a later occurring TRPM8 channel desensitization in primary sensory neurons. These mechanisms may explain the transient cold allodynia after oxaliplatin treatment and highlight an important role of TRPM8 in oxaliplatin-induced acute and neuropathic pain. KW - oxaliplatin KW - TRPM8 KW - desensitization KW - acute pain KW - neuropathic pain Y1 - 2021 UR - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/61247 UR - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-612479 SN - 1422-0067 VL - 22 IS - 9, art. 4962 SP - 1 EP - 16 PB - Molecular Diversity Preservation International CY - Basel ER -